Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Field Trip Health Ltd (FTRP.TO)

Field Trip Health Ltd (FTRP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63,386
  • Shares Outstanding, K 11,630
  • Annual Sales, $ 4,860 K
  • Annual Income, $ -54,691 K
  • 60-Month Beta N/A
  • Price/Sales 12.95
  • Price/Cash Flow N/A
  • Price/Book 0.95
Trade FTRP.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -4.75
  • Most Recent Earnings $-1.25 on N/A
  • Latest Earnings Date 08/15/22
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year -0.20
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.01 +7.92%
on 08/02/22
1.23 -11.38%
on 07/20/22
unch (unch)
since 07/15/22
3-Month
0.97 +12.37%
on 06/23/22
1.28 -14.84%
on 05/18/22
-0.12 (-9.92%)
since 05/16/22
52-Week
0.93 +17.20%
on 05/10/22
7.75 -85.94%
on 10/19/21
-5.19 (-82.64%)
since 08/16/21

Most Recent Stories

More News
Stocks in play: Field Trip Health Ltd.

Plans to release financial results for its fiscal 2023 first quarter for the three-month period ended ...

FTRP.TO : 1.09 (+5.83%)
Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd. on the TSX Venture Exchange

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022....

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 0.4800 (-1.03%)
SILO : 1.8800 (+5.62%)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
ATAI : 1.8700 (-5.08%)
CYBN : 0.3550 (unch)
ENBI.CN : 0.2000 (-13.04%)
ENTBF : 0.1210 (+5.22%)
CMPS : 8.10 (-1.82%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

ENTBF : 0.1210 (+5.22%)
FTRP.TO : 1.09 (+5.83%)
SILO : 1.8800 (+5.62%)
FTRP : 4.2105 (+1.07%)
ATAI : 1.8700 (-5.08%)
CYBN : 0.3550 (unch)
CMPS : 8.10 (-1.82%)
Stocks in play: Field Trip Health Ltd.

Announced today the first successful dosings in the Phase 1 Clinical Study entitled “A Double-Blind, ...

FTRP.TO : 1.09 (+5.83%)
Field Trip Announces First Dosings in Phase I Clinical Study of FT-104

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio ...

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public...

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement...

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions...

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)
Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions...

FTRP-WT.TO : 0.0050 (unch)
FTRP : 4.2105 (+1.07%)
FTRP.TO : 1.09 (+5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Field Trip Health Ltd is engaged in the development and delivery of psychedelic therapies. Its operating segments include Clinical Operations, Research, and Corporate. With its Field Trip Discovery, the company's research division, leading the development of the next generation of psychedelic molecules...

See More

Key Turning Points

3rd Resistance Point 1.18
2nd Resistance Point 1.14
1st Resistance Point 1.12
Last Price 1.09
1st Support Level 1.06
2nd Support Level 1.02
3rd Support Level 1.00

See More

52-Week High 7.75
Fibonacci 61.8% 5.14
Fibonacci 50% 4.34
Fibonacci 38.2% 3.54
Last Price 1.09
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar